Provided by Tiger Fintech (Singapore) Pte. Ltd.

OnKure Therapeutics, Inc.

2.89
+0.20007.43%
Volume:159.10K
Turnover:450.43K
Market Cap:39.05M
PE:-0.33
High:2.89
Open:2.69
Low:2.68
Close:2.69
Loading ...

OnKure Therapeutics Inc. Conducted Annual Meeting of Stockholders

Reuters
·
29 May

Cormorant Asset Management Reports Disposal of Onkure Therapeutics Inc. Common Shares

Reuters
·
20 May

Acorn Bioventures, L.P. Reports Acquisition of Common Shares of Onkure Therapeutics Inc

Reuters
·
20 May

Cormorant Asset Management Reports Disposal of Common Shares in Onkure Therapeutics Inc

Reuters
·
15 May

Oppenheimer Keeps Their Buy Rating on OnKure Therapeutics (OKUR)

TIPRANKS
·
07 May

Onkure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate

Benzinga
·
06 May

Onkure Therapeutics Inc Q1 Loss per Share $1.19

THOMSON REUTERS
·
06 May

Onkure Therapeutics: $96.7 Mln Cash & Cash Equivalents Sufficient to Fund Ops Into Q4 2026

THOMSON REUTERS
·
06 May

Press Release: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Dow Jones
·
06 May

Onkure Therapeutics Inc expected to post a loss of $1.46 a share - Earnings Preview

Reuters
·
02 May

Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating

MT Newswires Live
·
30 Apr

We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate

Simply Wall St.
·
29 Mar

OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
18 Mar

Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies

TIPRANKS
·
12 Mar

OnKure Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
11 Mar

Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating

MT Newswires Live
·
11 Mar

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
11 Mar

Onkure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
11 Mar

Onkure Therapeutics: Expansion of Pi3ka Franchise to Include a Pan-Mutant Selective Program; Development Candidate Expected to Be Announced in Q2 2025

THOMSON REUTERS
·
11 Mar